Aesthetic health news.

In New York, on May 03, 2023 Regen Lab, Long Island University (LIU) and Dassault Systèmes celebrated a partnership rich in potential for the development of regenerative medicine research.
Regen Lab is a leading industrial innovator of medical device products for autologous regenerative medicine, based on the extemporaneous preparation of platelet-rich plasma (PRP, autologous thrombin, etc.) from patient blood, cell therapy (notably the extraction of MSC from bone marrow) and combination therapy (PRP combined with hyaluronic acid). To date, Regen Lab's patented technologies are available in over 160 countries worldwide and have been used to treat over 2 million patients in various therapeutic areas (musculoskeletal, dermal, wound care and intimacy), resulting in the publication of over 200 research projects. With Regen Lab now based in Saclay, France, and in New York, USA, key links are being developed with multi-disciplinary university research teams from Long Island University (LIU) and leading French and American teams brought together by Dassault Systèmes (France & US). A dynamic strategy has been drawn up for the next 5 years, with the following key R&D priorities, rich in potential. Investment highlights include the following. For a world-leading, profitable and prolific tissue engineering specialist like Regen Lab, here are the main transformative growth opportunities for the next five years: 1/ An integrated tissue engineering engine from intellectual property to manufacturing. 2/ Solid commercialization experience backed by a profitable, global portfolio. 3/ A strong pipeline of incremental innovations and transformational opportunities. 4/ A compact team of tissue engineering experts.
en_US

Aesthetic health based on scientific evidence

Sign up to view this latest issue and receive future issues of LM